Ebola drugs, vaccines advance; US frets
This article was originally published in Scrip
Ebola continued to dominate Washington and consumed much of the US conversation on 16 October as President Barack Obama suggested he may appoint a "czar" to oversee the situation and as top health and science leaders were hauled in front of Congress to explain why the nation appears so poorly prepared to handle the virus and what steps are being taken to get on track.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.